Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
IRVINE, Calif., Feb. 15, 2017 -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that it will release financial results for the three and 12 months ended December 31, 2016 after market close on Wednesday, February 22, 2017. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
| Live Call: | U.S.: | (866) 634-2258 |
| International: | (330) 863-3454 | |
| Live Webcast: | http://investor.combimatrix.com/events.cfm | |
| The webcast replay will be archived for 30 days | ||
| Replay: | U.S.: | (855) 859-2056 |
| International: | (404) 537-3406 | |
| Passcode: | 65848323 | |
| The telephone replay will be available for seven days | ||
About CombiMatrix Corporation
CombiMatrix Corporation provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. Our testing focuses on advanced technologies, including single nucleotide polymorphism (“SNP”) chromosomal microarray analysis (“CMA”), next generation sequencing (“NGS”), fluorescent in situ hybridization (“FISH”) and high resolution karyotyping. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Contact: LHA Jody Cain (310) 691-7100 [email protected]
